At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERNA Eterna Therapeutics Inc.
Trading 08-31 14:22:44 EDT
4.54
-0.03
-0.66%
High4.75Low4.54Vol6.96K
Open4.68D1 Closing4.57Amplitude4.59%
Mkt Cap7.41MTradable Cap5.52MTotal Shares1.63M
T/O32.45KT/O Rate0.57%Tradable Shares1.22M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement
Reuters  ·  08-28
Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement
Ernexa Therapeutics Posts On-Demand Video Webcast of Investor Presentation
Reuters  ·  08-27
Ernexa Therapeutics Posts On-Demand Video Webcast of Investor Presentation
Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Dow Jones  ·  08-10
Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview
Reuters  ·  08-08
Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview
Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue
Reuters  ·  08-07
Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue
Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors
Reuters  ·  07-24
Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
GlobeNewswire  ·  07-24
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am
Reuters  ·  07-15
NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am
Ernexa Therapeutics announces new ERNA-101 preclinical data
TIPRANKS  ·  07-15
Ernexa Therapeutics announces new ERNA-101 preclinical data
Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study
Reuters  ·  07-15
Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study
Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026
THOMSON REUTERS  ·  07-15
Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026
Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026
THOMSON REUTERS  ·  07-15
Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026
Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy
THOMSON REUTERS  ·  07-15
Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy
Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026
THOMSON REUTERS  ·  07-14
Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
GlobeNewswire  ·  07-14
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
Ernexa Therapeutics Holds Annual Shareholder Meeting
Reuters  ·  07-03
Ernexa Therapeutics Holds Annual Shareholder Meeting
Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3
Reuters  ·  06-27
Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
GlobeNewswire  ·  06-25
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
Ernexa expects FDA review of ERNA-101 IND in Q4 2026
Reuters  ·  06-17
Ernexa expects FDA review of ERNA-101 IND in Q4 2026
Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026
THOMSON REUTERS  ·  06-17
Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026

Introduction

Company Name.
Eterna Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Issue price:
--